Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers. - Wikidata - wikimedia - TriplyDB

Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.

Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.

http://www.wikidata.org/entity/Q36709856

about

Transcriptional regulation of chemokine expression in ovarian cancer Joint analysis of multiple high-dimensional data types using sparse matrix approximations of rank-1 with applications to ovarian and liver cancer Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.Tumor-associated macrophages and anti-tumor therapies: complex links.Tumour-associated macrophages as treatment targets in oncology.Tumor-Associated Macrophages as Target for Antitumor Therapy.Cancer associated fibroblasts: An essential role in the tumor microenvironment.Clinical evaluation of macrophages in cancer: role in treatment, modulation and challenges.A drug development perspective on targeting tumor-associated myeloid cells.Macrophages: The Road Less Traveled, Changing Anticancer Therapy.CCL2-SQSTM1 positive feedback loop suppresses autophagy to promote chemoresistance in gastric cancer.Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment

P2860

Q26825361-66588305-C153-48BC-A550-D365BE59375E Q28595658-5D261A3F-083E-4554-9B44-274352FE1CD9 Q33829740-0DDA4D68-75D4-4C16-BDDE-39022F05FAC2 Q35550226-31D257C0-E357-4DDB-962F-08E479C6B882 Q36679410-CCA3BBF2-CC93-4758-B2C1-D6A6F7156B1C Q38766176-9A1056A9-2214-4EF1-9DC3-6CFEA670571F Q39100693-02712A20-53C0-453A-BB5C-4BF9A8DAF197 Q39403895-6047F6FE-9AC9-4E1B-ABF9-87EE3A0AAEFA Q41614004-70695E7F-7846-4586-930B-5D34BCA044CE Q48290538-7D78DC63-8132-4D1F-8177-7D3ED9F7553B Q48652546-F972775D-329A-4571-8EF3-FE69473E7C93 Q52321369-55287923-90CB-4736-9D35-95ADE2D11BC3 Q55513244-2A59D1CE-0A4C-4DEB-94E6-CAC208DE52CB Q57817490-F194DF77-DFD6-49A8-9F4A-EC1EAC464245 Q58712309-813DE005-BCF8-488E-A0A4-D698EAD36745

P2860

Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.

http://www.wikidata.org/entity/Q36709856

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.

@ast

Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.

@en

type

label

Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.

@ast

Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.

@en

prefLabel

Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.

@ast

Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.

@en

P1433

Q36709856-F7608397-8CD9-4F15-8533-90805B3AF16C

P1476

Q36709856-C260EEE2-637B-4A7F-ABE5-5046D9A9EFCC

P2093

Q36709856-17E487E5-AF5C-4F1C-8DA9-F3A09A329838

Q36709856-1C1D97E6-B7A1-476B-81E8-0DFFF834A835

Q36709856-37B26252-8EF7-4A83-A392-A686783CD18D

Q36709856-62A3E7FA-EF81-4AC2-8D67-AD6D34D108D4

Q36709856-E27CED0D-5C2E-4873-BECF-76E607AD81AB

Q36709856-E45ABFA0-52D6-455E-8F88-FE0AB4F68F6C

Q36709856-E68B22C7-8781-4958-8CA8-5BD7AD3718AF

Q36709856-F245389F-A36F-4177-9A75-9837BEC9B6DA

P2860

Q36709856-1FD2642E-EA64-4368-A984-01A1F66B95B2

Q36709856-1FFD58BB-A8F0-4027-A5B5-96BBEE2CE35B

Q36709856-24F59FD7-25DE-4779-B80B-148F03093CD2

Q36709856-2C130E43-D1A9-4F79-8DB2-76A63F55AD8F

Q36709856-38225B5E-5D50-4BE3-BE80-0AFB96C9CA63

Q36709856-41E2C0B7-354A-4706-941C-9390A1869EE8

Q36709856-473322ED-6D08-45AA-B5F8-CD8E32DF3BD0

Q36709856-4A39291E-A4AB-4CBB-8B78-BA740CCD3A31

Q36709856-53932E2D-775B-4C1C-A53D-24E04620D4CB

Q36709856-5846F9A4-DA28-4174-A73A-12F4E7AC2561

P304

Q36709856-3962E213-EFF5-46FD-B510-7146BC99039E

P31

Q36709856-25EFE5A4-E863-40A4-8BE9-AB5AD6C7959F

P356

Q36709856-35127F25-B016-412E-8FFE-312419C62F0D

P433

Q36709856-E857358E-0857-4DF3-925D-529BBAA5233E

P478

Q36709856-8FE2ED7D-9F8F-41AE-B9D6-1EFBED5EAF5B

P50

Q36709856-96DB3D74-C893-4B17-BD7D-4CF4413FA8F2

Q36709856-CD379E65-0DD4-48F2-AE11-A9E1F34EC47D

P577

Q36709856-5685F49F-BCDB-4CD6-A69C-51A545560243

P5875

Q36709856-32521361-450F-4297-8B5D-D4CAE6E57A70

P698

Q36709856-C9F4C4F0-FE19-4993-8B10-1D7799858170

P921

Q36709856-200AC035-E744-47AE-86FB-BA637DB5B866

P932

Q36709856-7BAA4DBD-4B6B-432C-BA8F-04B858BA6D15

P356

J.MOLONC.2014.03.016

P1433

Molecular Oncology

P1476

Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers

@en

P2093

Branimir I Sikic

http://www.w3.org/2001/XMLSchema#string

Edgar B Francisco

http://www.w3.org/2001/XMLSchema#string

George E Duran

http://www.w3.org/2001/XMLSchema#string

Linda A Snyder

http://www.w3.org/2001/XMLSchema#string

Parul Doshi

http://www.w3.org/2001/XMLSchema#string

Shalini Chaturvedi

http://www.w3.org/2001/XMLSchema#string

Shobha Seetharam

http://www.w3.org/2001/XMLSchema#string

Yan C Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Gene expression patterns in ovarian carcinomas

Structural basis for high selectivity of anti-CCL2 neutralizing antibody CNTO 888

Mechanisms of cancer drug resistance

The many roles of chemokines and chemokine receptors in inflammation

Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data.

Molecular pathways: regulation and therapeutic implications of multidrug resistance

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.

Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells.

Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells

P304

1231-1239

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.MOLONC.2014.03.016

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Anamaria Brozovic

François Moisan

P577

2014-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261038811

http://www.w3.org/2001/XMLSchema#string

P698

24816187

http://www.w3.org/2001/XMLSchema#string

P921

P932

4801026

http://www.w3.org/2001/XMLSchema#string